CLDX - Celldex Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CLDX is currently covered by 5 analysts with an average price target of $83.39. This is a potential upside of $62.94 (307.78%) from yesterday's end of day stock price of $20.45.

Celldex Therapeutics's activity chart (see below) currently has 57 price targets and 82 ratings on display. The stock rating distribution of CLDX is 88.89% BUY, 2.78% SELL and 8.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 22.78% with an average time for these price targets to be met of 69.36 days.

Highest price target for CLDX is $67, Lowest price target is $37, average price target is $62.4.

Most recent stock forecast was given by JOSEPH PANTGINIS from HC WAINWRIGHT on 09-May-2025. First documented stock forecast 19-Dec-2008.

Currently out of the existing stock ratings of CLDX, 32 are a BUY (88.89%), 1 are a SELL (2.78%), 3 are a HOLD (8.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$50

$31.67 (172.78%)

$80

8 days ago
(09-May-2025)

6/30 (20%)

$31.67 (172.78%)

256

Buy

$67

$48.67 (265.52%)

$67

3 months 18 days ago
(28-Jan-2025)

4/18 (22.22%)

$41.49 (162.64%)

62

Hold

$37

$18.67 (101.85%)

$35

9 months 5 days ago
(12-Aug-2024)

4/4 (100%)

$3.54 (10.58%)

165

Buy

$90

$71.67 (391.00%)

$72

1 years 2 months 20 days ago
(26-Feb-2024)

0/4 (0%)

$38.96 (76.33%)

Buy

$68

$49.67 (270.98%)

$70

1 years 9 months 6 days ago
(11-Aug-2023)

0/3 (0%)

$37.77 (124.94%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CLDX (Celldex Therapeutics) average time for price targets to be met?

On average it took 69.36 days on average for the stock forecasts to be realized with a an average price target met ratio 22.78

Which analyst has the current highest performing score on CLDX (Celldex Therapeutics) with a proven track record?

BIREN AMIN

Which analyst has the most public recommendations on CLDX (Celldex Therapeutics)?

Biren Amin works at PIPER SANDLER and has 6 price targets and 5 ratings on CLDX

Which analyst is the currently most bullish on CLDX (Celldex Therapeutics)?

Jonathan Aschoff with highest potential upside - $437.48

Which analyst is the currently most reserved on CLDX (Celldex Therapeutics)?

Mara Goldstein with lowest potential downside - -$15.33

Celldex Therapeutics in the News

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology...

Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8%. A quarter ago, it was...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?